SPRO
Spero Therapeutics Inc
NASDAQ: SPRO · HEALTHCARE · BIOTECHNOLOGY
$2.51
-0.79% today
Updated 2026-04-30
Market cap
$154.60M
P/E ratio
17.80
P/S ratio
2.31x
EPS (TTM)
$0.15
Dividend yield
—
52W range
$1 – $3
Volume
0.4M
Spero Therapeutics Inc (SPRO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-9.61M | $-28.96M | $-39.11M | $-39.63M | $-50.02M | $-85.87M | $-64.35M | $-7.73M | $-32.99M | $-23.44M | $-12.62M |
| Capital expenditures | $232000.00 | $830000.00 | $27000.00 | $2.44M | $314000.00 | $157000.00 | $64.35M | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $21000.00 | $180000.00 | $1.43M | $2.75M | $3.78M | $4.89M | $9.43M | $9.12M | $7.93M | $7.79M | $4.33M |
| Free cash flow | $-9.84M | $-29.79M | $-39.14M | $-42.06M | $-50.33M | $-86.03M | $-128.69M | $-7.73M | $-32.99M | $-23.44M | $-12.62M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | — | — | — | $47.48M | $54.48M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $76.97M | $-53.26M | $-4.35M | $55.48M | — | — | — | — | — |